We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 32.00 | 1.91% | 1,705.00 | 1,701.00 | 1,701.50 | 1,718.50 | 1,673.00 | 1,685.50 | 5,853,296 | 16:35:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.21 | 70.03B |
From May 2021 to May 2024
By Cecilia Butini
GlaxoSmithKline PLC said Friday that a Covid-19 vaccine developed with South Korea-based SK Bioscience Co. has met its co-primary objectives in a Phase 3 study, demonstrating superior antibody levels compared with AstraZeneca PLC's shot, which was chosen as a control vaccine.
The British pharmaceutical major said that the vaccine, which is called SKYCovione and uses Glaxo's adjuvant technology, showed a clinically acceptable safety profile, with most postvaccine adverse reactions being mild or moderate.
SK Bioscience will apply for emergency-use listing with the World Health Organization and authorization at individual regulatory agencies around the world. The company had already signed an advance purchase agreement with South Korea for a total of 10 million doses, Glaxo said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 29, 2022 04:08 ET (08:08 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
